GlobeNewswire Inc | Nov 1, 2021 03:34PM EDT

November 01, 2021

NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. (DBV or the Company) (NASDAQ:DBVT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Ampli and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On October 26, 2021, DBV disclosed that it had received communication from the FDA [U.S. Food and Drug Administration] concerning [DBVs] STAMP protocol submission of May 6, 2021. DBV advised investors that [t]he FDA has requested a stepwise approach to DBVs modified Viaskin Peanut (mVP) development program. The FDA would like to review the data from DBVs protein uptake release study prior to providing additional comments on the STAMP protocol design.

On this news, DBVs stock price fell $1.45 per share, or 28.71% to close at $3.60 on October 27, 2021.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT:Robert S. WilloughbyPomerantz LLPrswilloughby@pomlaw.com888-476-6529 ext. 7980